AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24115184 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 800 IU/d
Number of subjects: 0
Study 24115184 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 2000 mg/d and Vitamin D3 800 IU/d
Number of subjects: 0
Study 24115184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23845522 — intervention group
Group type: EXPERIMENTAL
Intervention: CPRO device
Number of subjects: 24
Study 23845522 — intervention group
Group type: COMPARATOR
Intervention: MCPR
Number of subjects: 24
Study 21934308 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted gastrectomy (LAG)
Number of subjects: 123
Study 21934308 — intervention group
Group type: COMPARATOR
Intervention: Open gastrectomy (OG)
Number of subjects: 123
Study 19537528 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (generic alternative)
Number of subjects: 72
Study 19537528 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (standard preparation)
Number of subjects: 72
Study 16740440 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation (DS) - 60 mg iron, 200 mcg folic acid, 1 mcg vitamin B12 daily
Number of subjects: 116
Study 16740440 — intervention group
Group type: COMPARATOR
Intervention: Weekly supplementation (WS) - two tablets once weekly
Number of subjects: 116
Study 16740440 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoconcentration (both groups)
Number of subjects: 116
Study 15327611 — intervention group
Group type: EXPERIMENTAL
Intervention: New cervical cell sampler (the implement)
Number of subjects: 220
Study 15327611 — intervention group
Group type: COMPARATOR
Intervention: Jordan's spatula (control)
Number of subjects: 220
Study 11526270 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG trigger at 40% (group 1)
Number of subjects: 274
Study 11526270 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG trigger at 50% (group 2)
Number of subjects: 274
Study 11526270 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG trigger at 60% (group 3)
Number of subjects: 274
Study 11526270 — intervention group
Group type: COMPARATOR
Intervention: ECG trigger at 80% (group 4)
Number of subjects: 274
Study 11526270 — intervention group
Group type: EXPERIMENTAL
Intervention: Untriggered group (group 5)
Number of subjects: 274
Study 9547830 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation
Number of subjects: 0
Study 9547830 — intervention group
Group type: COMPARATOR
Intervention: Other factors (e.g., heredity, social class, maternal age, etc.)
Number of subjects: 0
Study 11271215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretransplant blood transfusions (at least three random blood transfusions), n = 86
Number of subjects: 171
Study 11271215 — intervention group
Group type: COMPARATOR
Intervention: No pretransplant transfusion, n = 85
Number of subjects: 171
Study 3418689 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-mail campaign
Number of subjects: 99
Study 3418689 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 99
Study 3418689 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 99
Study 29133549 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7667 (10 mg/kg of each antibody, 4 doses at transplant, 1, 4, and 8 weeks)
Number of subjects: 120
Study 29133549 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 60)
Number of subjects: 120
Study 28786337 — intervention group
Group type: EXPERIMENTAL
Intervention: In-reach rehabilitation team
Number of subjects: 214
Study 28786337 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 214
Study 25105458 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried fermentate (EpiCor(®))
Number of subjects: 12
Study 25105458 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 12
Study 23660846 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial laser therapy (TLT)
Number of subjects: 640
Study 23660846 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 640
Study 21367352 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg at bedtime
Number of subjects: 24
Study 21367352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18714238 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial Concurrent Exercise (CE)
Number of subjects: 50
Study 18714238 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Concurrent Exercise (CE)
Number of subjects: 50
Study 18714238 — intervention group
Group type: COMPARATOR
Intervention: Integrated CE
Number of subjects: 50
Study 16526898 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) signals measured in healthy adults over 6 months
Number of subjects: 0
Study 16526898 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS signal amplitudes
Number of subjects: 0
Study 16526898 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance between activation centers identified in two sessions
Number of subjects: 0
Study 12882067 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of metoclopramide
Number of subjects: 60
Study 12882067 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric insufflation of 350 mL of air
Number of subjects: 60
Study 10837440 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 300 mg bd for 5 days
Number of subjects: 548
Study 10837440 — intervention group
Group type: COMPARATOR
Intervention: Cefprozil 500 mg bd for 10 days
Number of subjects: 548
Study 10203402 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g MgSO4
Number of subjects: 67
Study 10203402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 8410924 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 28
Study 8410924 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 28
Study 3011885 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 1‐17 (100 micrograms)
Number of subjects: 19
Study 3011885 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 1‐17 (random infusion)
Number of subjects: 19
Study 3011885 — intervention group
Group type: COMPARATOR
Intervention: Saline (random infusion)
Number of subjects: 19
Study 3011885 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 1‐17
Number of subjects: 19
Study 29029053 — intervention group
Group type: EXPERIMENTAL
Intervention: qHPV vaccine
Number of subjects: 2084
Study 27887581 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist guided Internet-based CBT program
Number of subjects: 248
Study 27887581 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management Internet-based CBT program
Number of subjects: 248
Study 27887581 — intervention group
Group type: COMPARATOR
Intervention: Usual care, waiting list control group
Number of subjects: 248
Study 27887581 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Internet-based CBT programs (therapist guided and self-management)
Number of subjects: 248
Study 24507091 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 300 mg twice daily
Number of subjects: 100
Study 24507091 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 mg riboflavin capsules)
Number of subjects: 100
Study 23648372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis (115 mg Δ9-THC, twice daily)
Number of subjects: 21
Study 23648372 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cannabis flowers with THC extracted)
Number of subjects: 21
Study 21677596 — intervention group
Group type: EXPERIMENTAL
Intervention: High acculturation
Number of subjects: 504
Study 21677596 — intervention group
Group type: EXPERIMENTAL
Intervention: Low acculturation
Number of subjects: 504
Study 18971605 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Enteral Nutrition (EEN)
Number of subjects: 60
Study 18971605 — intervention group
Group type: COMPARATOR
Intervention: Early Natural Nutrition (ENN)
Number of subjects: 60
Study 16610922 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 485
Study 16610922 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone-acetaminophen
Number of subjects: 485
Study 12544676 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 91
Study 12544676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 11712308 — intervention group
Group type: EXPERIMENTAL
Intervention: Amilorid (10 mg)
Number of subjects: 41
Study 11712308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (500 mg)
Number of subjects: 41
Study 8793307 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg three times daily
Number of subjects: 61
Study 8793307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 8793307 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 61
Study 1451725 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-571 (L-660,711) administered intravenously, single doses up to 1500 mg
Number of subjects: 26
Study 1451725 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-571 (L-660,711) administered orally, multiple doses of 100, 300, and 600 mg t.i.d. for 31 doses
Number of subjects: 26
Study 6837255 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml mepivacaine with adrenaline
Number of subjects: 150
Study 6837255 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml mepivacaine with adrenaline
Number of subjects: 150
Study 6837255 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 ml mepivacaine with adrenaline
Number of subjects: 150
Study 6837255 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (20 ml, 40 ml, 80 ml)
Number of subjects: 150
Study 31594062 — intervention group
Group type: EXPERIMENTAL
Intervention: CCLG-ALL 2008 protocol
Number of subjects: 84
Study 31594062 — intervention group
Group type: EXPERIMENTAL
Intervention: CCLG-ALL 2008 protocol (intermediate risk group)
Number of subjects: 84
Study 31594062 — intervention group
Group type: EXPERIMENTAL
Intervention: CCLG-ALL 2008 protocol (high risk group)
Number of subjects: 84
Study 29451912 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant imatinib treatment for one or three years
Number of subjects: 400
Study 26994121 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued thienopyridine
Number of subjects: 3391
Study 26994121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3391
Study 26994121 — intervention group
Group type: EXPERIMENTAL
Intervention: Thienopyridine plus aspirin (after 12 months)
Number of subjects: 3391
Study 24605717 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 gram honey
Number of subjects: 97
Study 24605717 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 gram honey
Number of subjects: 97
Study 24605717 — intervention group
Group type: COMPARATOR
Intervention: 75 gram glucose
Number of subjects: 97
Study 22252353 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic supplementation (with prebiotic)
Number of subjects: 40
Study 22252353 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CP level (85% of NRC-recommended level)
Number of subjects: 40
Study 22252353 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal stocking density (10 birds/m²)
Number of subjects: 40
Study 22252353 — intervention group
Group type: COMPARATOR
Intervention: High stocking density (16 birds/m²)
Number of subjects: 40
Study 22252353 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactions between protein level and stocking density
Number of subjects: 40
Study 19837791 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 0
Study 19837791 — intervention group
Group type: COMPARATOR
Intervention: Control group (less intensive training and follow-up)
Number of subjects: 0
Study 17592346 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cm H2O positive end-expiratory pressure (PEEP)
Number of subjects: 53
Study 17592346 — intervention group
Group type: COMPARATOR
Intervention: No PEEP (Control Group)
Number of subjects: 53
Study 15833301 — intervention group
Group type: EXPERIMENTAL
Intervention: Reach-first intervention (infants grasp objects before watching another person grasp similar objects)
Number of subjects: 0
Study 15833301 — intervention group
Group type: COMPARATOR
Intervention: Watch-first intervention (infants watch another person grasp similar objects before grasping objects themselves)
Number of subjects: 0
Study 15833301 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in object-directed contact with toys
Number of subjects: 0
Study 11872654 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 7
Study 11872654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 11872654 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and Exercise
Number of subjects: 7
Study 11872654 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 7
Study 11872654 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 7
Study 10195381 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET) 500 mg twice daily
Number of subjects: 28
Study 10195381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (DEX) 15 mg thrice daily
Number of subjects: 28
Study 10195381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10195381 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (MET, DEX, Placebo)
Number of subjects: 28
Study 8547378 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular follow-up visits by a geriatric team at 1, 3, 8 and 16 weeks after discharge
Number of subjects: 193
Study 8547378 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 193
Study 2317464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 22
Study 2317464 — intervention group
Group type: COMPARATOR
Intervention: Intravenous phenytoin sodium
Number of subjects: 22
Study 7364321 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (0.3 mg per kg)
Number of subjects: 14
Study 7364321 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (0.3 mg per kg)
Number of subjects: 14
Study 29558241 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism adaptation treatment for 10 days
Number of subjects: 0
Study 29558241 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 31068272 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg
Number of subjects: 657
Study 31068272 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir 50 mg with co-formulated emtricitabine 200 mg and tenofovir alafenamide 25 mg
Number of subjects: 657
Study 31068272 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir group
Number of subjects: 657
Study 31068272 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir group
Number of subjects: 657
Study 26857103 — intervention group
Group type: EXPERIMENTAL
Intervention: SCION-HSCT intervention (standard care plus SCION-HSCT)
Number of subjects: 79
Study 26857103 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 79
Study 25888343 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured individual counseling session by a pharmacist in addition to written orientations
Number of subjects: 380
Study 25888343 — intervention group
Group type: COMPARATOR
Intervention: Written information about the disease
Number of subjects: 380
Study 24144900 — intervention group
Group type: EXPERIMENTAL
Intervention: Site nurse-initiated adherence and symptom support telephone calls
Number of subjects: 333
Study 24144900 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no additional calls)
Number of subjects: 333
Study 21861419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (0.5 microg x kg(‐1) x hr(‐1))
Number of subjects: 45
Study 21861419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (0.4‐0.7 microg x kg(‐1) x hr(‐1) decreased to 0.2‐0.7 microg x kg(‐1) x hr(‐1))
Number of subjects: 45
Study 21861419 — intervention group
Group type: COMPARATOR
Intervention: Control group (no continuous intravenous analgesia)
Number of subjects: 45
Study 19623196 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium treatment for 2 months
Number of subjects: 40
Study 19623196 — intervention group
Group type: COMPARATOR
Intervention: Dietary measures alone (Control group)
Number of subjects: 40
Study 19623196 — intervention group
Group type: COMPARATOR
Intervention: Both groups (G1 and G2)
Number of subjects: 40
Study 17173009 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate eye drops
Number of subjects: 68
Study 17173009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 68
Study 15613142 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study 15613142 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0
Study 12397274 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water irrigation
Number of subjects: 69
Study 12397274 — intervention group
Group type: COMPARATOR
Intervention: Control (room temperature water)
Number of subjects: 69
Study 10188743 — intervention group
Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI) meal
Number of subjects: 8
Study 10188743 — intervention group
Group type: COMPARATOR
Intervention: Low Glycemic Index (LGI) meal
Number of subjects: 8
Study 8534294 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioscrew (bioabsorbable interference screw)
Number of subjects: 110
Study 8534294 — intervention group
Group type: COMPARATOR
Intervention: Metal screw (metal interference screw)
Number of subjects: 110
Study 8534294 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioscrew
Number of subjects: 110
Study 8534294 — intervention group
Group type: COMPARATOR
Intervention: Metal screw
Number of subjects: 110
Study 8534294 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioscrew and Metal screw
Number of subjects: 110
Study 2196143 — intervention group
Group type: EXPERIMENTAL
Intervention: olestra (18 gm/day for 28 days)
Number of subjects: 28
Study 2196143 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 319120 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensin, 75 mg/day
Number of subjects: 40
Study 319120 — intervention group
Group type: COMPARATOR
Intervention: Viloxazine, 150 mg/day
Number of subjects: 40
Study 31127757 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive jaw opening exercise (RJOE) using a portable device
Number of subjects: 40
Study 31127757 — intervention group
Group type: COMPARATOR
Intervention: Placebo group performing RJOE using a sham device with fewer loads
Number of subjects: 40
Study 31308269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridge augmentation using non‐resorbable ePTFE membrane only
Number of subjects: 150
Study 31308269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridge augmentation using ePTFE and tenting screw with bone graft Bio‐Oss mixed with autogenous bone particles
Number of subjects: 150
Study 31308269 — intervention group
Group type: COMPARATOR
Intervention: Ridge augmentation with a bone block
Number of subjects: 150
Study 28450193 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily prednisone
Number of subjects: 300
Study 28450193 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily deflazacort
Number of subjects: 300
Study 28450193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent prednisone (10 days on/10 days off)
Number of subjects: 300
Study 24898537 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib 50mg weekly (ODN)
Number of subjects: 214
Study 24898537 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 214
Study 23497156 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month intervention program including individual counseling and group sessions
Number of subjects: 1983
Study 23497156 — intervention group
Group type: COMPARATOR
Intervention: Control group (1,040 participants)
Number of subjects: 1983
Study 22036245 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride/metformin 1/500 mg SR
Number of subjects: 33
Study 22036245 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride/metformin 2/500 mg SR
Number of subjects: 33
Study 22036245 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 33
Study 17658628 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl L-carnitine (ALC)
Number of subjects: 96
Study 16425133 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of H. pylori infection plus iron supplementation for 6 weeks
Number of subjects: 219
Study 16425133 — intervention group
Group type: COMPARATOR
Intervention: Control group (iron supplementation only)
Number of subjects: 219
Study 12868803 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 56000
Study 12868803 — intervention group
Group type: COMPARATOR
Intervention: Dose-dense chemotherapy
Number of subjects: 56000
Study 12868803 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (substituted for fluorouracil in combination with doxorubicin and cyclophosphamide)
Number of subjects: 56000
Study 10950898 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg bd
Number of subjects: 45
Study 10950898 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 100 microg bd
Number of subjects: 45
Study 10950898 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 200 microg qds
Number of subjects: 45
Study 8624320 — intervention group
Group type: COMPARATOR
Intervention: No biopsy
Number of subjects: 161
Study 8624320 — intervention group
Group type: EXPERIMENTAL
Intervention: Central biopsy
Number of subjects: 161
Study 8624320 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral biopsy
Number of subjects: 161
Study 1471549 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-effervescent Antabuse tablets (400 mg DSF after overnight fast)
Number of subjects: 30
Study 1471549 — intervention group
Group type: COMPARATOR
Intervention: Effervescent Antabuse tablets (800 mg DSF after a light standardized meal)
Number of subjects: 30
Study 6235082 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 27